Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis - Wikidata - awgldk - TriplyDB

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis

http://www.wikidata.org/entity/Q58714957

about

Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis

http://www.wikidata.org/entity/Q58714957

description

article publié dans la revue scientifique PLoS ONE

@fr

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published in PLoS ONE

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Hepatic decompensation during ...... osis and compensated cirrhosis

@en

Hepatic decompensation during ...... osis and compensated cirrhosis

@nl

type

label

Hepatic decompensation during ...... osis and compensated cirrhosis

@en

Hepatic decompensation during ...... osis and compensated cirrhosis

@nl

prefLabel

Hepatic decompensation during ...... osis and compensated cirrhosis

@en

Hepatic decompensation during ...... osis and compensated cirrhosis

@nl

P1433

Q58714957-673F5DBD-5A2F-44D4-B9DB-48DD2DD806CC

P1476

Q58714957-DE717BFA-69CD-4F05-A7CA-5468F094FCED

P2093

Q58714957-30611CB2-7331-4FB5-A49D-A554D969B140

Q58714957-3CA72FC1-6E29-496D-A675-AF675625654D

Q58714957-4343224A-968D-443B-9619-3058ABEFC9F8

Q58714957-5F085931-974C-4E88-ABD9-53B89C198762

Q58714957-6D7D7B7A-3A56-41E5-A3F9-36CCAAECD6BE

Q58714957-B3486AB4-DCAC-41FE-BA48-0CB7974B292E

Q58714957-D0CD513F-7B08-457D-80A3-6F98DE6DBA2C

Q58714957-D1BF7F19-0C0F-44B5-917B-B400B482D026

Q58714957-F1C500B6-F3FB-460E-809F-C481466C3BD5

P2860

Q58714957-0D148AD7-46FE-4E0F-BA80-EA131860497F

Q58714957-106D1F55-8A45-4CF1-8173-7C56850936FF

Q58714957-138F6E28-CA5F-401C-B7C5-992E50DE4E60

Q58714957-2CABBE23-995D-4EDD-AC2B-0E2B5CA82DC3

Q58714957-303F8CB1-0BB1-47B1-9624-CE57E48768A5

Q58714957-3221AD24-2C9F-4DAC-8DE3-D82B0CC217A5

Q58714957-33177ED7-8744-4712-A3B3-3ECFFB92F2BC

Q58714957-3620CF83-BBB2-429B-B19A-D09B1455AE62

Q58714957-43226DE2-73F0-4983-A00D-BD199A877600

Q58714957-4411F580-AF86-46AF-9B63-C0DB42DB7E36

P304

Q58714957-96973355-4169-434A-962E-8E425A366E46

P31

Q58714957-C65EBCDB-4403-43BE-ACB5-023820B39F75

P356

Q58714957-0AE57EDA-5CD4-4CD9-80C2-C52FB5DF4AB8

P407

Q58714957-29E622F3-6258-4DF0-ADCA-F95832EBE1A7

P433

Q58714957-FEE6F845-C3CA-4351-A5F7-02EF51191678

P478

Q58714957-B6B15750-FB57-430E-8DF4-0BB99ED0A34D

P50

Q58714957-A0D5E827-57FB-4621-88B8-3CA863E10AFC

P577

Q58714957-ECF93660-CB01-434E-9FB7-97B8C18F7F71

P698

Q58714957-3B5C6CB4-2658-4D70-A1B1-066EF3F6FB50

P932

Q58714957-50A4028B-CE24-4865-BBFF-F5A362B44D7C

P356

JOURNAL.PONE.0202777

P1433

P1476

Hepatic decompensation during ...... osis and compensated cirrhosis

@en

P2093

Chien-Hao Huang

http://www.w3.org/2001/XMLSchema#string

Chun-Yen Lin

http://www.w3.org/2001/XMLSchema#string

Dar-In Tai

http://www.w3.org/2001/XMLSchema#string

I-Shyan Sheen

http://www.w3.org/2001/XMLSchema#string

Shi-Ming Lin

http://www.w3.org/2001/XMLSchema#string

Wei Teng

http://www.w3.org/2001/XMLSchema#string

Wei-Ting Chen

http://www.w3.org/2001/XMLSchema#string

Wen-Juei Jeng

http://www.w3.org/2001/XMLSchema#string

Yi-Cheng Chen

http://www.w3.org/2001/XMLSchema#string

P2860

Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection

Global epidemiology and genotype distribution of the hepatitis C virus infection

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.

Real world efficacy and safety of ombitasvir, Paritaprevir/r+Dasabuvir+Ribavirin IN genotype 1B patients with HCV liver cirrhosis.

Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.

HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study.

P304

e0202777

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0202777

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

P577

2018-08-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30138456

http://www.w3.org/2001/XMLSchema#string

P932

6107263

http://www.w3.org/2001/XMLSchema#string